YARW · Yarrow Bioscience, Inc.
$33.00
+2.55 (+8.37%)
At close · Jul 30
Market Cap
$952.56M
Shares
33.35M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| David Domzalski | CEO | $1,973,607 |
| Iain Stuart | CSO | $908,430 |
| Mutya Harsch | General Counsel | $891,515 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| David Domzalski | CEO | $2,716,350 |
| Iain Stuart | CSO | $1,164,946 |
| Mutya Harsch | General Counsel | $1,126,090 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| David Domzalski | CEO | $1,293,464 |
| Mutya Harsch | General Counsel | $654,410 |
| Iain Stuart | CSO | $653,926 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| David Domzalski | CEO | $4,852,925 |
| Mutya Harsch | General Counsel | $1,312,106 |
| Iain Stuart | CSO | $1,287,359 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| David Domzalski | CEO | $2,872,008 |
| Steven Basta | CEO | $1,614,942 |
| Andrew Saik | CFO | $1,536,537 |
| Mutya Harsch | General Counsel | $907,196 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Steven Basta | CEO | $1,878,181 |
| Kristine Ball | CFO | $898,376 |
| Paul Kwon | Former Chief Scientific Officer | $892,888 |
| Andrew Saik | CFO | — |
| Mutya Harsch | General Counsel | — |
| David Domzalski | CEO | — |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Steven Basta | CEO | $2,605,865 |
| Kristine Ball | CFO | $1,265,478 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| all of the Company's directors | directors | Resigned | 2026-07-28 |
| Anthony Bruno | member of the Board and as a member of the Compensation Committee and the Nominating and Corporate Governance Committee | Resigned | 2025-08-14 |
| Christine Borowski, Ph.D. | member of the Board and as a member of the Nominating and Corporate Governance Committee | Resigned | 2025-08-14 |